Hanneke Schuitemaker | CSO
Valneva Austria GmbH

Hanneke Schuitemaker, Ph.D., has been Valneva’s Chief Scientific Officer since June 2024 and, as such, responsible for the pre-clinical and translational R&D and CMC strategy and execution, working on prophylactic vaccines against chikungunya, Lyme disease, Zika, Shigella, EBV and ETEC. Prior to Valneva, she served for almost 14 years as the Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson Innovative Medicine, overseeing vaccine programs for HIV, RSV, Ebola, Zika, COVID-19, IPV and HPV. She is also a Professor in Virology at the Amsterdam University Medical Center and specialized during her 20+ years academic career in the pathogenesis of HIV infection.